N@N

NASHUA, N.H. & MIAMI--([ BUSINESS WIRE ])--[ iCAD, Inc. ] (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today the launch of a post-market study to assess the safety and efficacy of the companyas FDA-cleared [ Xoft Axxent eBxa" System ] when used for single-fraction, intra-operative radiation therapy (IORT) at the time of lumpectomy for early stage breast cancer. A historical comparison will be made to the current standard of care, external beam radiation therapy (EBRT). The announcement was made during the 29^th Annual [ Miami Breast Cancer Conference ] where iCAD is showcasing the Xoft System.

"Compliance rates with EBRT vary widely between different populations based on proximity to care, length of treatment, and other factors. The use of Xoftas technology significantly expands patient access to this potentially life-saving treatment. This study underscores iCADas continued commitment to advancing the field of cancer detection and treatment."

aWhile many breast surgeons and radiation oncologists have already experienced the benefits of treating early stage breast cancer patients with a single dose of radiation during lumpectomy, external beam after lumpectomy remains the current standard of care, subjecting many patients to weeks of daily radiation treatments,a said Helena Chang, MD, PhD, University of California Los Angeles and co-principal investigator for the study. aThis study will enable users of the Xoft System to treat patients with suitable early stage breast cancer under a standardized IORT protocol and follow long-term patient outcomes in a controlled manner.a

The study, aA Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer,a is a prospective, multi-center, historical control trial. Researchers plan to enroll up to 1,000 patients at as many as 50 study sites across the U.S. and Europe. Study subjects will be followed for 10 years after treatment to determine the safety and efficacy of IORT with the Xoft System, and interim data will be collected on an annual basis. The studies will also assess cosmetic outcomes and quality of life for subjects treated with Xoft IORT.

aWe believe the results from this study will further validate existing data showing IORT to be as safe and effective as external beam radiation, positioning the Xoft System as a treatment alternative that may be delivered more conveniently while improving a patientas quality of life,a said Ken Ferry, President and CEO of iCAD. aCompliance rates with EBRT vary widely between different populations based on proximity to care, length of treatment, and other factors. The use of Xoftas technology significantly expands patient access to this potentially life-saving treatment. This study underscores iCADas continued commitment to advancing the field of cancer detection and treatment.a

iCAD is currently seeking investigative sites to participate in this study. For more information contact Michael Patz, Director of Clinical Affairs at iCAD at [ mpatz@icadmed.com ] or visit [ www.clinicaltrials.gov ].

About Xoft

The Xoft eBxa" Electronic Brachytherapy System from iCAD is an isotope-free (non-radioactive) radiation treatment cleared by the FDA for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer and skin cancer. The Xoft System utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. Xoft eBxa" can be administered as a single course of radiation therapy during surgery in the form of intraoperative radiation therapy (IORT) or in the form of partial breast irradiation (APBI). The Xoft System does not require a shielded environment and the systemas relatively small size and mobility allow for it to be used in virtually any clinical setting. For more information about Xoft visit [ www.xoftinc.com ]

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent eBxa" electronic brachytherapy system (eBx). Axxent uses isotope-free, miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit [ www.icadmed.com ].

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Companyas ability to defend itself in litigation matters, the risks relating to the Companyas acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCADas and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Companyas filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, awilla, acontinuea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at [ http://www.icadmed.com ] and on the SECas website at [ http://www.sec.gov ].